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Abstract
Background: Epidemiological studies indicate a statistical linkage between atherosclerotic vascular disease (ATH)
and Alzheimer’s disease (AD). Autopsy studies of cardiac disease in AD have been few and inconclusive. In this
report, clinical and gross anatomic measures of cardiac disease were compared in deceased human subjects with
and without AD.
Methods: Clinically documented cardiovascular conditions from AD (n = 35) and elderly non-demented control
subjects (n = 22) were obtained by review of medical records. Coronary artery stenosis and other gross anatomical
measures, including heart weight, ventricular wall thickness, valvular circumferences, valvular calcifications and
myocardial infarct number and volume were determined at autopsy.
Results: Compared to non-demented age-similar control subjects, those with AD had significantly fewer total
diagnosed clinical conditions (2.91 vs 4.18), decreased coronary artery stenosis (70.8 vs 74.8%), heart weight (402 vs
489 g for males; 319 vs 412 g for females) and valvular circumferences. Carriage of the Apolipoprotein E-ε4 allele
did not influence the degree of coronary stenosis. Group differences in heart weight remained significant after
adjustment for age, gender, body mass index and apolipoprotein E genotype while differences in coronary artery
stenosis were significantly associated with body mass index alone.
Conclusions: The results are in agreement with an emerging understanding that, while midlife risk factors for ATH
increase the risk for the later development of AD, once dementia begins, both risk factors and manifest disease
diminish, possibly due to progressive weight loss with increasing dementia as well as disease involvement of the
brain’s vasomotor centers.
Background
Alzheimer’s disease (AD) is the most common neurode-
generative brain disease and the most common cause of
dementia in the elderly. The disease has a progressive
course over several years that often leaves the victim
uncommunicative and bedridden. Five million Ameri-
cans have AD and the cost of the disease to the US is
estimated at $100 billion annually. Finding a cure or
prevention for AD is an important national goal. Over
the last decade considerable evidence has accumulated
supporting a statistical linkage between atherosclerotic
vascular disease (ATH) and AD. Several established risk
factors for atherosclerosis, including hypertension,
hypercholesterolemia, diabetes, cigarette smoking and
the apolipoprotein E- ε4 allele have also been found to
be risk factors for the development of AD [1-3]. This
has important implications since major complications of
ATH such as myocardial infarction and stroke are to a
significant degree preventable through lifestyle modifica-
tion and medications. If ATH and AD share aspects of
their pathogenesis, AD may also be to some extent pre-
ventable through similar measures.
The relationship between AD and ATH is complex,
however, and not completely understood. While elevated
midlife ATH risk factors appear to increase the risk for
developing AD in late life [4-6], once dementia begins, * Correspondence: thomas.beach@bannerhealth.com
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molecular changes associated with AD, to decreased
caloric intake and/or increased caloric expenditure
or to reduced survival of those with high ATH risk
factors [7-9].
The majority of the evidence linking AD and ATH has
come from epidemiological and clinical studies. These
are compromised by the inaccuracy of the clinical diag-
nosis of AD [10] and by the mostly indirect determina-
tions of the presence and extent of ATH. Autopsy
studies are a powerful method for investigating this
issue as they offer a high diagnostic accuracy for AD
and direct and accurate measures of ATH. To date,
autopsy studies have reported a strong relationship
between intracranial ATH and AD [11-13] while the
correlation with coronary artery disease (CAD) has been
less clear. Some groups have found a strong association
[14-16] while others have failed to find an association
[17,18]. A common limitation of these studies has been
that the assessment of the degree of CAD has been
solely through gross semi-quantitative estimates of the
extent of stenosis, done routinely at autopsy and not
specifically intended for research use. In this report, cor-
onary artery stenosis in 57 deceased human subjects
with and without a neuropathological diagnosis of AD
was quantitatively assessed at multiple points along the
coronary arterial system using computer-assisted image
analysis. These measures, as well as measures of myo-
cardial infarction volume, heart weight, ventricular wall
thickness, valve circumferences and valve calcifications,
were compared in AD and non-demented age-similar
control subjects. Additionally, the prevalence of clini-
cally-reported cardiovascular conditions and the apoli-
poprotein E (apoE) genotype were compared in the two
groups.
Methods
The study took place as part of the Banner Sun Health
Research Institute Brain and Body Donation Program,
which is a longitudinal, clinicopathologic study of nor-
mal aging and neurodegenerative disease in volunteers
derived primarily from the surrounding retirement com-
munities of Sun City, Sun City West, and Sun City
Grand, Arizona [19]. The Program is approved by the
Institutional Review Board of Banner Health, a regional,
not-for-profit health care provider. Written informed
consent was obtained from all subjects or their legal
representatives.
Standardized clinical assessments were performed on
most subjects every one to two years and at a minimum
included a medical and family history questionnaire,
height and weight measurements, the Folstein Mini-
Mental State Examination (MMSE), one or more func-
tional cognitive assessments and a neuropsychological
test battery consisting of specific elements relating to
attention, memory, language, visuospatial function and
frontal/executive function. Dementia was diagnosed
according to DSM-IV criteria, requiring an impairment
of memory with one other abnormality of cognition,
functional disability, and preservation of consciousness.
The neuropathological diagnosis of AD was made
according to standardized criteria (National Institute on
Aging/Reagan Institute “intermediate” or “high” prob-
ability”) [20]. Inclusion criteria specified subjects whose
autopsy had included the heart and had either a neuro-
pathological diagnosis of AD or who had been clinically
non-demented. Exclusion criteria specified subjects with
a cause of dementia other than AD, including vascular
dementia. Global cerebral senile plaque and neurofibril-
lary tangle load scores were obtained by summation of
separate semi-quantitative density estimates of none,
sparse, moderate or frequent (converted to 0-3 for sta-
tistical purposes) using standardized published templates
[21]. Regions scored included cortical gray matter from
frontal, parietal, temporal, hippocampal and entorhinal
regions.
The epicardial coronary arteries were dissected out
and then both arteries and hearts were fixed in forma-
lin at 4 degrees C for 10 days followed by storage in
phosphate-buffered saline with 0.1% sodium azide.
The right coronary artery, marginal branch, right pos-
terior descending, left coronary artery, circumflex
artery and left anterior descending artery were cut
every 5 mm into cross-sections that were examined
using a Leica S8APO dissecting microscope. Digital
photographs of the cross-sections were taken and
measurements of the arteries’ external and luminal
areas were calculated using a desktop minicomputer
with dedicated software (ImagePro Express, v.4.0;
Media Cybernetics, Silver Spring, MD). An index of
stenosis was calculated for each cross-section by sub-
tracting the intraluminal area from the total area,
dividing the difference by the total area and multiply-
ing the quotient by 100. Hearts with surgical coronary
artery bypasses (4 control subjects and 3 AD subjects)
were excluded from the analysis.
Other heart measurements included heart weight, left
and right ventricular wall thickness, valvular circumfer-
ences, presence or absence of valvular calcification and
presence and volume of myocardial infarctions (MI). To
assess the last-named, the left and right ventricles were
sliced axially at 1 cm intervals and the number and
volume of grossly-visible myocardial scars determined.
The Body Mass Index (BMI) was calculated for each
subject from the last recorded height and weight mea-
surements prior to death. ApoE genotyping was
done with postmortem brain tissue using a standard
technique [22].
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were reviewed to record the number of cardiovascular
risk factors and disease conditions that had been clini-
cally diagnosed. These were grouped into the following
categories: hypertension, hyperlipidemia/dyslipidemia,
diabetes mellitus (type II), CAD, myocardial infarction,
carotid artery disease, congestive heart failure, stroke/
transient ischemic attack (TIA), valvular disease, periph-
eral arterial disease and arrhythmia. The timespan cov-
ered by the medical records available for review was
also recorded.
Medication history is obtained from subjects at the
time of their scheduled clinical research assessments.
The analysis included all cardiovascular-related medica-
tions, grouped by medication class, that had been taken
on the final clinical assessment. The medication classes
were designated as anti-angina, anti-arrhythmia, anti-
platelet, anti-diabetes, anti-hypertensive and lipid-lower-
ing agents.
Statistical tests included unpaired, two-tailed t-tests to
compare group means for individual measures, chi-
square tests and Fisher’s Exact tests for proportional dif-
ferences, and logistic regression analysis to assess the
independent effects on cardiovascular pathology mea-
sures of diagnosis, age, gender, BMI and apoE genotype.
The significance level for all tests was set at 0.05.
Results
General characteristics of the two groups are presented
in Table 1. The mean ages did not differ (83.7 for the
AD group and 84.4 for the control group). As expected,
the mean MMSE score was significantly lower in the
AD group. The mean BMI was also significantly lower
in the AD group (23.2 vs 26.2 for controls). The inter-
vals between the final MMSE and BMI determinations
and death were not significantly different between the
two groups. Measures of both senile plaques and neuro-
fibrillary tangles were significantly greater in the AD
group; the AD group had significantly lower mean brain
weight and a significantly higher proportion of subjects
carrying the apoE-ε4 allele.
The prevalence of clinically documented cardiovascu-
lar risk factors and disease conditions in the diagnostic
groups is shown in Table 2. The mean number of
months covered by the available private medical records
did not significantly differ between groups. Subjects
with AD had significantly fewer total recorded condi-
tions than control subjects (2.91 vs 4.18; p < 0.01) and
had lower prevalences of each of the condition cate-
gories recorded except for stroke/transient ischemic
attack for which there was a higher prevalence in the
AD subjects (45.7% vs 27.3%; p = 0.13). Of individual
condition categories, only the prevalence of congestive
heart failure was significantly different between the diag-
nostic groups (2.9% vs 36.4% for AD and controls,
respectively; p < 0.01). There was a trend for peripheral
v a s c u l a rd i s e a s et ob el e s sc o m m o ni nA D( 8 . 6 %v s
27.3%; p = 0.07). For every medication class except anti-
platelet agents, a smaller proportion of AD subjects
were taking the agents (Table 3). The proportional dif-
ferences were significant for anti-hypertensive agents
(25.9% of AD subjects vs 71.4% for control subjects).
Figure 1 depicts gross photographs of representative
coronary artery cross-sections, displaying the range of
atherosclerotic stenosis observed. Differences between
the two groups were not qualitatively apparent. As the
index of stenosis within the diagnostic groups was not
significantly different between different coronary artery
Table 1 General characteristics of the study subjects
Characteristic AD N = 35 C N = 22
Age (years) 83.7 (6.6) 84.4 (6.0)
Gender (M:F) 16:19 15:7
BMI 23.2 (4.0)
2 26.2 (4.1)
MMSE
1 10.40 (7.93)
2 28.53 (1.61)
Senile plaque density score 2.8 (0.38)
2 1.4 (1.3)
Neurofibrillary tangle density score 4.6 (1.2)
2 2.8 (0.91)
Brain weight (g) 1093 (132)
3 1209 (101)
Number and percentage with
the ApoE ε4 allele
15 (42.8%)
3 4 (18.2%)
1. MMSE not available for 5 AD and 2 control subjects.
2. Significantly different from control (p < 0.01).
3. Significantly different from control (p < 0.05).
Means and standard deviations are shown. AD = Alzheimer’s disease; C =
non-demented elderly controls; BMI = body mass index; MMSE = mini mental
state examination; ApoE = Apolipoprotein E.
Table 2 Clinically documented cardiovascular risk factors
and disease conditions amongst study subjects
Condition AD Control
Hypertension 22/35 (62.8%) 18/22 (81.8%)
Hyperlipidemia/Dyslipidemia 14/35 (40%) 12/22 (54.5%)
Diabetes mellitus 7/35 (20%) 7/22 (31.8%)
Coronary Artery Disease 15/35 (42.9%) 11/22 (50%)
Myocardial infarction 5/35 (14.3%) 5/22 (22.7%)
Arrhythmia 13/35 (37.1%) 13/22 (59.1%)
Valvular disorder 2/35 (5.7%) 3/22 (13.6%)
Congestive heart failure 1/35 (2.9%)
1 8/22 (36.4%)
Carotid artery disease 2/35 (5.7%) 3/22 (13.6%)
Stroke/Transient ischemic attack 16/35 (45.7%) 6/22 (27.3%)
Peripheral vascular disease 3/35 (8.6%) 6/22 (27.3%)
Total Number of Conditions 2.91 (1.64)
1 4.18 (1.84)
Timespan covered by records (months) 73.5 (50.8) 82.1 (73.4)
1. Significantly different from control (p < 0.01).
Values shown are proportions and percentages affected within each
diagnostic group, except for the total number of conditions and the timespan
covered by the available medical records, where the means and standard
deviations are shown.
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carriage of the apoE-ε4 allele, the data from all coronary
branches and all subjects was combined for further
comparison of the diagnostic groups. Figure 2 graphi-
cally compares the mean index of stenosis in coronary
arteries from AD and control subjects. The graph is a
class-frequency histogram, with the height of the col-
umns being proportional to the percentage of cross-sec-
tions with a particular index of stenosis range. The
entire histogram is shifted to the right for control sub-
jects, indicating a higher proportion of cross-sections
with a higher index of stenosis. The means for all cross-
sections are also shown for the two groups; these dif-
fered significantly, with a greater mean index of stenosis
in the control group (74.8 vs 70.8; p = 0.02).
A greater proportion of control subjects had myocar-
dial infarctions (50% vs 28.6%) but this did not meet the
significance level (p = 0.10). The mean MI volume was
higher in control subjects than in AD subjects (3.56 vs
1.65 cm
3) but the again the difference was not significant.
Other heart measurements including heart weight, left
and right ventricle mean thickness, and valve circumfer-
ences are presented in Table 4, grouped by diagnosis and
gender. For both males and females, the control group
had greater mean heart weights as well as greater mean
tricuspid and mitral valve circumferences. The difference
in heart weight was particularly striking, with mean heart
weights from male and female control subjects being 87
and 93 grams heavier than those from male and female
AD hearts, respectively. The difference between female
control and AD heart weights was significant (p < 0.05)
while the difference between male heart weights was
close to the significance level (p = 0.08). Mitral and tri-
cuspid valve circumferences were significantly greater in
female control subjects as compared to female AD sub-
jects (p < 0.01). Ventricular thickness did not differ sig-
nificantly between the groups but there was a trend for
thicker left and right ventricular walls in the control
group for both genders. Body mass index was higher in
the control group for both genders (Table 4) and the dif-
ference in means reached the significance level for
females (p < 0.01) but not for males (p = 0.09).
Tricuspid valve calcification was uncommon and there
were no subjects with pulmonary valve calcification.
Mitral and aortic valve calcification was present in 50%
Table 3 Proportion and percentage of subjects taking
cardiovascular-related medication types at the last
clinical assessment prior to death
Medication Class Alzheimer’s Control
Anti-angina 0 (0%) 1 (4.8%)
Anti-arrhythmia 2 (7.4%) 2 (9.5%)
Anti-platelet 13 (48.1%) 7 (33.3%)
Anti-diabetic 2 (7.4%) 5 (23.8%)
Anti-hypertensive 7 (25.9%)* 15 (71.4%)
Lipid-lowering 5 (18.5%) 6 (28.6%)
* p < 0.05, Fisher’s exact test.
There were no significant differences between groups except for the
proportion taking anti-hypertensive agents. Data was available for 27 AD
subjects and 21 control subjects.
Figure 1 Representative digital images of coronary artery cross-sections, depicting the range of atherosclerotic stenosis amongst
study subjects. Arteries from control subjects are shown in (A) while arteries from AD subjects are shown in (B).
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groups did not differ significantly for any of the valves.
Logistic regression analysis was performed to further
investigate the two major findings, i.e. decreased heart
weight and decreased coronary artery stenosis in AD
subjects. Assignment of greater pathology status was
based on measurements above the median value for all
subjects. The analysis was primarily for the effect of
diagnostic status as AD or control and was adjusted for
age, gender, apoE genotype and BMI. Diagnostic status
had a significant effect (p < 0.05, Wald p-value) on
heart weight. None of the other variables had a signifi-
cant association with heart weight but BMI was close to
the significance level (p = 0.067, Wald p-value) and thus
may have been significant with a larger subject number.
Controls were 4.47 times more likely (OR = 4.47) to
have increased heart weights. For the analysis of coron-
ary artery stenosis, diagnostic status had no significant
effect while BMI was the sole significant variable (p <
0.05, Wald p value). Each point increase in BMI was
associated with a 1.24% increase in coronary artery ste-
nosis (OR = 1.24).
Discussion
The “vascular hypothesis” of AD is as old as the disease
itself, as many early investigators assumed that AD was
caused by cerebral atherosclerosis. Others, including
Alzheimer himself, believed that the two processes were
unrelated. The relationship between AD and cerebrovas-
cular disease was eventually revised to the point of com-
plete separation due to a series of postmortem
investigations during the 1950’s and 1960’s [23].
The discovery in 1993 of the association of the apoE-
ε4 allele with AD [24] revived interest in the vascular
hypothesis as the ε4 allele was already known to be
associated with coronary atherosclerosis. Subsequent
epidemiologic and clinical investigations have estab-
lished that multiple additional ATH risk factors are also
risk factors for AD [1-3]. There have been relatively few
confirmatory autopsy studies but the published reports
to date indicate a strong relationship between intracra-
nial ATH and AD [11-13,25] while the correlation with
CAD has been less clear [14-18]. The present study has
utilized precise coronary artery stenosis measurements
and neuropathologically examined subjects in an
attempt to provide more clarity on this subject. Addi-
tionally, measures of general heart pathology have been
compared.
Coronary Artery Stenosis
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Figure 2 Class frequency histogram comparing the index of
stenosis in coronary artery disease cross-sections from AD
(blue) and control (red) groups. The means and standard
deviations for all cross-sections from AD and control groups are also
shown; the difference was significant (p = 0.02).
Table 4 Comparison of heart weight, ventricular thickness, and valve circumferences, with respect to diagnosis and
gender
Category AD Male Control Male AD Female Control Female
Heart Weight (g) 402 (131) 489 (136) 319 (99)
1 412 (69)
Mean LV greatest thickness (cm) 1.4 (0.19) 1.51 (0.27) 1.4 (0.21) 1.43 (0.39)
Mean RV greatest thickness (cm) 0.46 (0.05) 0.48 (0.10) 0.40 (0.08) 0.47 (0.13)
BMI 23.9 (4.00) 26.5 (3.81) 22.6 (3.94)
1 28.4 (4.67)
Tricuspid valve circumference (cm) 11.21 (1.70) 11.49 (1.59) 9.9 (1.04)
2 11.5 (1.32)
Pulmonary valve circumference (cm) 9.15 (0.90) 8.23 (0.96) 7.45 (0.90) 7.81 (0.98)
Mitral valve circumference (cm) 10.49 (1.83) 10.89 (0.94) 8.95 (0.87)
2 10.26 (1.44)
Aortic valve circumference (cm) 9.86 (1.11) 8.93 (1.17) 8.15 (0.86) 7.5 (0.50)
1. Significantly different from female control subjects (p < 0.05).
2. Significantly different from female control subjects (p < 0.01).
Means and standard deviations are shown. LV = left ventricle; RV = right ventricle; BMI = body mass index.
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vascular health in the AD group. Of ten clinically docu-
mented cardiovascular risk factors or disease conditions,
nine occurred more frequently in the control group.
Only stroke/TIA was more frequent in the AD subjects.
In terms of gross anatomy, the control group had
greater coronary artery stenosis, a greater proportion
with myocardial infarcts, larger myocardial infarcts,
greater heart weights, thicker ventricular walls and
greater triscuspid and mitral valve circumferences. For
every medication class except anti-platelet agents, a
smaller proportion of AD subjects were taking the
agents, making it unlikely that these findings were due
to increased anti-cardiovascular disease treatment in AD
subjects.
Previous autopsy studies of the heart in AD are rela-
tively scarce but are mostly in agreement with the pre-
sent study. Heart weights, in particular, have been
r e p o r t e dt ob el o w e ri nA Di nt w op r e v i o u ss t u d i e s
[15,26]. One previous study has reported less coronary
artery stenosis in subjects with AD [17]. Two studies by
another group [18,27] did not report directly on coron-
ary artery atherosclerosis but instead used a cardiovas-
cular pathology index (CVI) composed of several gross
anatomical measures including heart weight, coronary
artery atherosclerosis, myocardial infarctions, peripheral
artery atherosclerosis and intracranial atherosclerosis.
Their results showed less cardiovascular pathology in
AD and an inverse correlation with the densities of the
histopathologic lesions of AD. One group reported
mildly increased CAD in AD subjects [15]. Possible rea-
sons for the discrepancy between this last study and the
present report are the smaller size and lower BMI of the
control group in the previous study (N = 12; BMI =
23.0) as compared to the present study (N = 22; BMI =
26.2). It is possible that the method of assessing CAD
differed between the two studies but as this was not
described in the previous study no conclusions can be
made regarding this issue. To our knowledge, the pre-
sent study is the first to use precise, computer-assisted
image analysis to determine the degree of coronary
artery stenosis in AD and control subjects.
Although the apoE-ε4 allele has been reported to be
associated with clinical CAD, the present findings are in
agreement with studies finding no association. In terms
of the interaction of the ε4 allele with both coronary
atherosclerosis and AD, one study has reported that the
ε4 allele correlated with increased coronary athero-
sclerosis within AD subjects [26] but did not compare
coronary atherosclerosis in AD subjects with that in
control subjects. Another study reported that the degree
of coronary atherosclerosis correlated with the density
of AD-related histopathologic lesions in subjects carry-
ing the ε4 allele [15].
The results of this study support an emerging body of
data consistent with decreased cardiovascular risk fac-
tors and disease conditions in elderly subjects with AD
[27-29]. This has been somewhat surprising as authori-
tative reports from groups conducting population-based
longitudinal studies have indicated that ATH risk factors
including hypertension and hypercholesterolemia, when
present in midlife, are strongly predictive for the devel-
opment of AD in late life [4-6]. It has been postulated
that the reversal of cardiovascular pathology in elderly
AD subjects may arise due to molecular or neuropatho-
logical factors [7-9] associated with AD. For example,
brainstem neurons that contribute to vasomotor regula-
tion are lost in AD and this could result in decreased
blood pressure and heart weight. Although we did not
have longitudinal data confirming progressive weight
loss over time in our AD subjects, this has been docu-
mented in several longitudinal studies [30-33] and there-
fore it seems likely that this plays a major role as well.
Conclusions
The present study has found consistently decreased
measures of both clinical and gross anatomic indices of
cardiovascular disease, including coronary artery stenosis
and cardiac hypertrophy, in elderly AD subjects as com-
pared with age-similar non-demented subjects. The rea-
sons for this are uncertain but may be due to
progressive weight loss in AD subjects as well as to dis-
ease-specific effects on brain vasomotor regulatory
neurons.
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